RASMUSSEN UNIVERSITY — COLLEGE OF NURSING
NU R2 407 ONLY
Pharmacology Exam
1
A comprehensive 75-question examination covering
pharmacokinetics and pharmacodynamics, medication safety
and calculations, autonomic nervous system pharmacology,
central nervous system pharmacology, cardiovascular
pharmacology, and integrated clinical nursing scenarios
aligned with the 2026–2027 curriculum.
Total Questions: 75 | Format: Multiple Choice (A–D)
Academic Year: 2026–2027 | Cognitive Levels: Recall / Application / Analysis
C O N F I D E N T I A L E X A M I N AT I O N M AT E R I A L LATES T 20 27 ED ITION
,NUR2407/2407 ONLY: Pharmacology Exam 1 (Latest 2026/2027)
Rasmussen University
75 Questions | Multiple Choice | Time: 2 Hours
Instructions: Select the BEST answer for each question.
Section 1: Pharmacokinetics and Pharmacodynamics (ADME, Receptor
Theory, & Drug Interactions)
Questions 1–12
Q1. A nurse is administering medication via the intravenous (IV) route. Which statement best describes the
bioavailability of IV medications?
A. Bioavailability is approximately 80% due to partial first-pass metabolism
B. Bioavailability is 100% because the medication bypasses first-pass metabolism [CORRECT]
C. Bioavailability is variable depending on gastric emptying time
D. Bioavailability is reduced due to protein binding in the bloodstream
Correct Answer: B
Rationale: IV administration bypasses the gastrointestinal tract and first-pass hepatic metabolism, resulting in 100%
bioavailability. Oral medications undergo first-pass metabolism in the liver before reaching systemic circulation,
reducing bioavailability. Gastric emptying affects oral absorption, not IV. Protein binding affects distribution, not
bioavailability directly.
Q2. A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass metabolism.
What should the nurse anticipate?
A. Increased risk of drug toxicity due to decreased first-pass metabolism [CORRECT]
B. Decreased drug effect due to enhanced hepatic clearance
C. No change in drug effect because first-pass metabolism is unaffected
D. Increased drug excretion through the renal route
Correct Answer: A
Rationale: In liver cirrhosis, hepatic function is impaired, reducing first-pass metabolism. This allows more of the drug to
reach systemic circulation, increasing bioavailability and the risk of toxicity. The nurse should anticipate the need for
dosage reduction. Hepatic clearance is decreased, not enhanced. Renal excretion is not directly affected by first-pass
metabolism.
Q3. A nurse is caring for a patient receiving warfarin (Coumadin). The patient is also taking phenytoin
(Diazepam), which is highly protein-bound. What is the pharmacokinetic concern?
A. Decreased effect of warfarin due to increased free warfarin metabolism
B. Increased risk of bleeding due to displacement of warfarin from protein-binding sites [CORRECT]
C. No interaction because both drugs bind to different proteins
D. Increased protein binding of both drugs leading to reduced effect
Correct Answer: B
Rationale: Both warfarin and phenytoin are highly protein-bound (primarily to albumin). When given together, phenytoin
can displace warfarin from protein-binding sites, increasing the free (active) concentration of warfarin and elevating
bleeding risk. Only the unbound/free drug is pharmacologically active. This is a pharmacokinetic drug interaction
affecting the distribution phase.
, Q4. A patient is taking a drug that is a strong CYP3A4 inducer. Which effect should the nurse expect?
A. Decreased metabolism of CYP3A4 substrates, leading to increased drug levels
B. Increased metabolism of CYP3A4 substrates, leading to decreased drug levels [CORRECT]
C. No effect on the metabolism of concurrent medications
D. Inhibition of renal excretion of other medications
Correct Answer: B
Rationale: CYP3A4 inducers (e.g., carbamazepine, rifampin) increase the activity of the cytochrome P450 enzyme
system, accelerating the metabolism of drugs that are CYP3A4 substrates. This leads to decreased serum drug levels and
potentially reduced therapeutic effects. The nurse should monitor for decreased efficacy of concurrent
CYP3A4-substrate medications. CYP inducers increase, not decrease, metabolism.
Q5. Which of the following best describes the mechanism of action of an agonist drug?
A. Binds to a receptor and blocks the action of endogenous neurotransmitters
B. Binds to a receptor and partially activates it, producing a submaximal response
C. Binds to a receptor and activates it, mimicking the endogenous neurotransmitter [CORRECT]
D. Stabilizes the receptor in its inactive conformation
Correct Answer: C
Rationale: An agonist binds to a receptor and activates it, producing the same or similar response as the endogenous
neurotransmitter. A full agonist produces a maximal response. A partial agonist (option B) produces only a submaximal
response even when all receptors are occupied. An antagonist (option A) blocks receptor activation. An inverse agonist
(option D) stabilizes the inactive state.
Q6. A nurse is reviewing the medication profile of a patient prescribed lithium (Lithobid). Which statement
about the therapeutic index is most accurate?
A. Lithium has a wide therapeutic index, making overdose unlikely
B. Lithium has a narrow therapeutic index, requiring regular serum drug monitoring [CORRECT]
C. The therapeutic index measures the maximum tolerated dose of a drug
D. The therapeutic index is unrelated to drug safety monitoring
Correct Answer: B
Rationale: Lithium has a narrow therapeutic index (therapeutic level 0.6–1.2 mEq/L, toxicity begins above 1.5 mEq/L),
requiring regular serum drug level monitoring. Drugs with a narrow therapeutic index include lithium, digoxin, warfarin,
and phenytoin. The therapeutic index is the ratio of the toxic dose to the effective dose; a higher TI indicates a safer drug.
Narrow TI drugs require therapeutic drug monitoring.
Q7. A patient is receiving two medications that have a synergistic interaction. What does the nurse understand
about this interaction?
A. The combined effect equals the sum of each individual drug effect
B. The combined effect is greater than the sum of each individual drug effect [CORRECT]
C. One drug reduces the effect of the other drug
D. The drugs cancel each other out, producing no effect
Correct Answer: B
Rationale: A synergistic interaction occurs when two drugs produce a combined effect that is greater than the sum of
their individual effects (1 + 1 > 2). An additive interaction (option A) means the combined effect equals the sum of
individual effects (1 + 1 = 2). An antagonistic interaction (option C) occurs when one drug reduces the effect of another.
Synergistic interactions require careful monitoring for enhanced therapeutic effects and adverse reactions.
Q8. Which phase of pharmacokinetics involves the movement of a drug from the bloodstream into tissues and
organs?
NU R2 407 ONLY
Pharmacology Exam
1
A comprehensive 75-question examination covering
pharmacokinetics and pharmacodynamics, medication safety
and calculations, autonomic nervous system pharmacology,
central nervous system pharmacology, cardiovascular
pharmacology, and integrated clinical nursing scenarios
aligned with the 2026–2027 curriculum.
Total Questions: 75 | Format: Multiple Choice (A–D)
Academic Year: 2026–2027 | Cognitive Levels: Recall / Application / Analysis
C O N F I D E N T I A L E X A M I N AT I O N M AT E R I A L LATES T 20 27 ED ITION
,NUR2407/2407 ONLY: Pharmacology Exam 1 (Latest 2026/2027)
Rasmussen University
75 Questions | Multiple Choice | Time: 2 Hours
Instructions: Select the BEST answer for each question.
Section 1: Pharmacokinetics and Pharmacodynamics (ADME, Receptor
Theory, & Drug Interactions)
Questions 1–12
Q1. A nurse is administering medication via the intravenous (IV) route. Which statement best describes the
bioavailability of IV medications?
A. Bioavailability is approximately 80% due to partial first-pass metabolism
B. Bioavailability is 100% because the medication bypasses first-pass metabolism [CORRECT]
C. Bioavailability is variable depending on gastric emptying time
D. Bioavailability is reduced due to protein binding in the bloodstream
Correct Answer: B
Rationale: IV administration bypasses the gastrointestinal tract and first-pass hepatic metabolism, resulting in 100%
bioavailability. Oral medications undergo first-pass metabolism in the liver before reaching systemic circulation,
reducing bioavailability. Gastric emptying affects oral absorption, not IV. Protein binding affects distribution, not
bioavailability directly.
Q2. A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass metabolism.
What should the nurse anticipate?
A. Increased risk of drug toxicity due to decreased first-pass metabolism [CORRECT]
B. Decreased drug effect due to enhanced hepatic clearance
C. No change in drug effect because first-pass metabolism is unaffected
D. Increased drug excretion through the renal route
Correct Answer: A
Rationale: In liver cirrhosis, hepatic function is impaired, reducing first-pass metabolism. This allows more of the drug to
reach systemic circulation, increasing bioavailability and the risk of toxicity. The nurse should anticipate the need for
dosage reduction. Hepatic clearance is decreased, not enhanced. Renal excretion is not directly affected by first-pass
metabolism.
Q3. A nurse is caring for a patient receiving warfarin (Coumadin). The patient is also taking phenytoin
(Diazepam), which is highly protein-bound. What is the pharmacokinetic concern?
A. Decreased effect of warfarin due to increased free warfarin metabolism
B. Increased risk of bleeding due to displacement of warfarin from protein-binding sites [CORRECT]
C. No interaction because both drugs bind to different proteins
D. Increased protein binding of both drugs leading to reduced effect
Correct Answer: B
Rationale: Both warfarin and phenytoin are highly protein-bound (primarily to albumin). When given together, phenytoin
can displace warfarin from protein-binding sites, increasing the free (active) concentration of warfarin and elevating
bleeding risk. Only the unbound/free drug is pharmacologically active. This is a pharmacokinetic drug interaction
affecting the distribution phase.
, Q4. A patient is taking a drug that is a strong CYP3A4 inducer. Which effect should the nurse expect?
A. Decreased metabolism of CYP3A4 substrates, leading to increased drug levels
B. Increased metabolism of CYP3A4 substrates, leading to decreased drug levels [CORRECT]
C. No effect on the metabolism of concurrent medications
D. Inhibition of renal excretion of other medications
Correct Answer: B
Rationale: CYP3A4 inducers (e.g., carbamazepine, rifampin) increase the activity of the cytochrome P450 enzyme
system, accelerating the metabolism of drugs that are CYP3A4 substrates. This leads to decreased serum drug levels and
potentially reduced therapeutic effects. The nurse should monitor for decreased efficacy of concurrent
CYP3A4-substrate medications. CYP inducers increase, not decrease, metabolism.
Q5. Which of the following best describes the mechanism of action of an agonist drug?
A. Binds to a receptor and blocks the action of endogenous neurotransmitters
B. Binds to a receptor and partially activates it, producing a submaximal response
C. Binds to a receptor and activates it, mimicking the endogenous neurotransmitter [CORRECT]
D. Stabilizes the receptor in its inactive conformation
Correct Answer: C
Rationale: An agonist binds to a receptor and activates it, producing the same or similar response as the endogenous
neurotransmitter. A full agonist produces a maximal response. A partial agonist (option B) produces only a submaximal
response even when all receptors are occupied. An antagonist (option A) blocks receptor activation. An inverse agonist
(option D) stabilizes the inactive state.
Q6. A nurse is reviewing the medication profile of a patient prescribed lithium (Lithobid). Which statement
about the therapeutic index is most accurate?
A. Lithium has a wide therapeutic index, making overdose unlikely
B. Lithium has a narrow therapeutic index, requiring regular serum drug monitoring [CORRECT]
C. The therapeutic index measures the maximum tolerated dose of a drug
D. The therapeutic index is unrelated to drug safety monitoring
Correct Answer: B
Rationale: Lithium has a narrow therapeutic index (therapeutic level 0.6–1.2 mEq/L, toxicity begins above 1.5 mEq/L),
requiring regular serum drug level monitoring. Drugs with a narrow therapeutic index include lithium, digoxin, warfarin,
and phenytoin. The therapeutic index is the ratio of the toxic dose to the effective dose; a higher TI indicates a safer drug.
Narrow TI drugs require therapeutic drug monitoring.
Q7. A patient is receiving two medications that have a synergistic interaction. What does the nurse understand
about this interaction?
A. The combined effect equals the sum of each individual drug effect
B. The combined effect is greater than the sum of each individual drug effect [CORRECT]
C. One drug reduces the effect of the other drug
D. The drugs cancel each other out, producing no effect
Correct Answer: B
Rationale: A synergistic interaction occurs when two drugs produce a combined effect that is greater than the sum of
their individual effects (1 + 1 > 2). An additive interaction (option A) means the combined effect equals the sum of
individual effects (1 + 1 = 2). An antagonistic interaction (option C) occurs when one drug reduces the effect of another.
Synergistic interactions require careful monitoring for enhanced therapeutic effects and adverse reactions.
Q8. Which phase of pharmacokinetics involves the movement of a drug from the bloodstream into tissues and
organs?
